

Changho Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5810463/publications.pdf>

Version: 2024-02-01

57
papers

2,596
citations

218592

26
h-index

189801

50
g-index

57
all docs

57
docs citations

57
times ranked

3534
citing authors

#	ARTICLE	IF	CITATIONS
1	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. <i>Nature Medicine</i> , 2012, 18, 624-629.	15.2	711
2	Metabolism of [¹³ C]glucose in human brain tumors <i>in vivo</i> . <i>NMR in Biomedicine</i> , 2012, 25, 1234-1244.	1.6	282
3	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. <i>Neuro-Oncology</i> , 2016, 18, 283-290.	0.6	161
4	Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With <i>IDH</i> -Mutant Glioma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4030-4039.	0.8	157
5	T2 measurement and quantification of glutamate in human brain <i>in vivo</i> . <i>Magnetic Resonance in Medicine</i> , 2006, 56, 971-977.	1.9	77
6	A comparative study of short- and long-TE ¹ H MRS at 3 T for <i>in vivo</i> detection of 2-hydroxyglutarate in brain tumors. <i>NMR in Biomedicine</i> , 2013, 26, 1242-1250.	1.6	73
7	T ₂ measurement of J-coupled metabolites in the human brain at 3T. <i>NMR in Biomedicine</i> , 2012, 25, 523-529.	1.6	72
8	Improvement of resolution for brain coupled metabolites by optimized ¹ H MRS at 7%T. <i>NMR in Biomedicine</i> , 2010, 23, 1044-1052.	1.6	70
9	Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. <i>NMR in Biomedicine</i> , 2012, 25, 1177-1186.	1.6	66
10	Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. <i>Journal of Neurosurgery</i> , 2018, 128, 391-398.	0.9	62
11	Compressive Sensing Could Accelerate ¹ H MR Metabolic Imaging in the Clinic. <i>Radiology</i> , 2012, 262, 985-994.	3.6	53
12	Measurement of brain glutamate and glutamine by spectrally-selective refocusing at 3 tesla. <i>Magnetic Resonance in Medicine</i> , 2006, 55, 997-1005.	1.9	51
13	Measurement of glycine in the human brain <i>in vivo</i> by ¹ H-MRS at 3 T: application in brain tumors. <i>Magnetic Resonance in Medicine</i> , 2011, 66, 609-618.	1.9	44
14	Measurement of <i>N</i> -acetylaspartylglutamate in the human frontal brain by ¹ H-MRS at 7 T. <i>Magnetic Resonance in Medicine</i> , 2010, 64, 1247-1251.	1.9	43
15	Proton T ₂ measurement and quantification of lactate in brain tumors by MRS at 3 Tesla <i>in vivo</i> . <i>Magnetic Resonance in Medicine</i> , 2015, 73, 2094-2099.	1.9	40
16	<i>In vivo</i> detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T. <i>Magnetic Resonance in Medicine</i> , 2017, 77, 936-944.	1.9	40
17	Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness. <i>Neuro-Oncology</i> , 2020, 22, 1018-1029.	0.6	37
18	Measurement of GABA and contaminants in gray and white matter in human brain <i>in vivo</i> . <i>Magnetic Resonance in Medicine</i> , 2007, 58, 27-33.	1.9	35

#	ARTICLE	IF	CITATIONS
19	Measurement of glycine in human brain by triple refocusing ¹ H MRS in vivo at 3.0T. <i>Magnetic Resonance in Medicine</i> , 2008, 59, 59-64.	1.9	32
20	Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics—Relevance to Glioma. <i>Frontiers in Neurology</i> , 2018, 9, 33.	1.1	32
21	Measurement of regional variation of GABA in the human brain by optimized point-resolved spectroscopy at 7T <i>in vivo</i> . <i>NMR in Biomedicine</i> , 2014, 27, 1167-1175.	1.6	30
22	Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 1851-1861.	1.9	30
23	Brain ¹³ -aminobutyric acid measurement by proton double-quantum filtering with selective rewinding. <i>Magnetic Resonance in Medicine</i> , 2005, 54, 272-279.	1.9	29
24	Proton spectral editing for discrimination of lactate and threonine 1.31 ppm resonances in human brain in vivo. <i>Magnetic Resonance in Medicine</i> , 2006, 56, 660-665.	1.9	29
25	Detection of 2-hydroxyglutarate in brain tumors by triple-refocusing MR spectroscopy at 3T in vivo. <i>Magnetic Resonance in Medicine</i> , 2017, 78, 40-48.	1.9	28
26	False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis. <i>Radiology</i> , 2019, 291, 752-762.	3.6	28
27	In vivo detection of serine in the human brain by proton magnetic resonance spectroscopy (¹ H MRS) at 7 Tesla. <i>Magnetic Resonance in Medicine</i> , 2009, 62, 1042-1046.	1.9	27
28	Enhanced neurochemical profile of the rat brain using in vivo ¹ H NMR spectroscopy at 16.4 T. <i>Magnetic Resonance in Medicine</i> , 2011, 65, 28-34.	1.9	22
29	Measurement of glycine in gray and white matter in the human brain in vivo by ¹ H MRS at 7.0 T. <i>Magnetic Resonance in Medicine</i> , 2012, 68, 325-331.	1.9	18
30	Phase-adjusted echo time (PATE) averaging ¹ H MRS: application for improved glutamine quantification at 2.89T. <i>NMR in Biomedicine</i> , 2012, 25, 1245-1252.	1.6	18
31	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. <i>Neuro-Oncology</i> , 2019, 21, vi28-vi29.	0.6	17
32	In vivo ¹ H MRS of glycine in brain tumors at 3T. <i>Magnetic Resonance in Medicine</i> , 2016, 75, 52-62.	1.9	16
33	Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status in Gliomas: The New Frontiers of Spectroscopy in Neurodiagnostics. <i>World Neurosurgery</i> , 2020, 133, e421-e427.	0.7	16
34	Measurement of glycine in human prefrontal brain by point-resolved spectroscopy at 7.0 tesla in vivo. <i>Magnetic Resonance in Medicine</i> , 2009, 62, 1305-1310.	1.9	15
35	Measurement of glutathione in human brain at 3T using an improved double quantum filter in vivo. <i>Journal of Magnetic Resonance</i> , 2009, 198, 160-166.	1.2	14
36	In vivo detection of citrate in brain tumors by ¹ H magnetic resonance spectroscopy at 3T. <i>Magnetic Resonance in Medicine</i> , 2014, 72, 316-323.	1.9	12

#	ARTICLE	IF	CITATIONS
37	In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH mutant xenograft mouse models versus glioma patients. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 1152-1160.	1.9	11
38	¹ H MRS characterization of neurochemical profiles in orthotopic mouse models of human brain tumors. <i>NMR in Biomedicine</i> , 2015, 28, 108-115.	1.6	10
39	Brief mindfulness training increased glutamate metabolism in the anterior cingulate cortex. <i>NeuroReport</i> , 2020, 31, 1142-1145.	0.6	10
40	Measurement of glycine in healthy and tumorous brain by triple-refocusing MRS at 3T in vivo. <i>NMR in Biomedicine</i> , 2017, 30, e3747.	1.6	9
41	3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 795-802.	1.9	9
42	Preoperative imaging of glioblastoma patients using hyperpolarized ¹³ C pyruvate: Potential role in clinical decision making. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab092.	0.4	9
43	In vivo T ₂ relaxation time measurement with echo-time averaging. <i>NMR in Biomedicine</i> , 2014, 27, 863-869.	1.6	7
44	Spectroscopy in neurodiagnostics: the new era. <i>Neuroradiology</i> , 2018, 60, 129-131.	1.1	7
45	Spectral fitting strategy to overcome the overlap between 2-hydroxyglutarate and lipid resonances at 2.25 ppm. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 1818-1828.	1.9	7
46	Detection of thymo-inositol 4.06-ppm resonance by selectiveJ rewinding: Application to human prefrontal cortex in vivo. <i>Magnetic Resonance in Medicine</i> , 2005, 54, 1536-1540.	1.9	6
47	Distinction of the GABA 2.29-ppm resonance using triple refocusing at 3T in vivo. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1307-1319.	1.9	6
48	Spectroscopic markers of neurodegeneration in the mesial prefrontal cortex predict survival in ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 246-251.	1.1	6
49	A randomized, double-blind, placebo-controlled trial of lamotrigine for prescription corticosteroid effects on the human hippocampus. <i>European Neuropsychopharmacology</i> , 2019, 29, 376-383.	0.3	5
50	RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi234-vi234.	0.6	4
51	Optimization of spectrally selective 180° radiofrequency pulse timings in J-difference editing (MEGA) of lactate. <i>Magnetic Resonance in Medicine</i> , 2022, 87, 1150-1164.	1.9	2
52	Shimming—the forgotten child of in-vivo MR?. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2021, 34, 179-181.	1.1	1
53	NIMG-13. GLYCINE IS A METABOLIC BIOMARKER OF MALIGNANCY IN GLIOMAS: IN VIVO MAGNETIC RESONANCE SPECTROSCOPY STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi164-vi164.	0.6	0
54	NIMG-08. 2-HYDROXYGLUTARATE MAGNETIC RESONANCE SPECTROSCOPY IN BRAINSTEM TUMOR PATIENTS IN VIVO. <i>Neuro-Oncology</i> , 2019, 21, vi163-vi163.	0.6	0

#	ARTICLE	IF	CITATIONS
55	BIMG-09. GLUTAMINE AND GLYCINE BY MR SPECTROSCOPY IDENTIFY AGGRESSIVE GLIOMAS. Neuro-Oncology Advances, 2021, 3, i2-i3.	0.4	0
56	NIMG-29. ELEVATION OF GLUTAMINE AND CITRATE BY MR SPECTROSCOPY IS AN IMAGING BIOMARKER OF RAPID CELL PROLIFERATION IN GLIOMAS. Neuro-Oncology, 2021, 23, vi135-vi135.	0.6	0
57	NIMG-24. GLYCINE AND GLUTAMINE BY MR SPECTROSCOPY ARE IMAGING BIOMARKERS OF GLIOMA AGGRESSIVENESS. Neuro-Oncology, 2020, 22, ii152-ii152.	0.6	0